Pulmonx Corporation (LUNG)
After hours:
| Previous close | 7.61 |
| Open | 7.70 |
| Bid | 7.68 x 100 |
| Ask | 7.84 x 100 |
| Day's range | 7.65 - 8.15 |
| 52-week range | 7.11 - 14.84 |
| Volume | |
| Avg. volume | 589,180 |
| Market cap | 299.627M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.20 |
- GuruFocus.com
Pulmonx Corp (LUNG) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Continued Losses
Insight into Pulmonx's Financial Health and Strategic Moves
GlobeNewswirePulmonx Reports First Quarter 2024 Financial Results
Achieves 30% year-over-year worldwide revenue growthREDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Recorded worldwide revenue of $18.9 million in the first quarter of 2024, a 30% increase over the same period last year and an increase of 29% on a constant currency basisD
- GlobeNewswire
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Inve
